IS THE ORPHANAGE FILLING UP? PROJECTING THE GROWTH AND BUDGET IMPACT OF ORPHAN DRUGS IN EUROPE

被引：4
|
作者：
Flostrand, S. [1 ]
Rodriguez, I [2 ]
Maddox, B. [3 ]
Finch, L. [3 ]
Belulaj, S. [3 ]
Gould, A. [4 ]
机构：
[1] IMS Consulting Grp, Paris, France
[2] IMS Consulting Grp, Madrid, Spain
[3] IMS Consulting Grp, Cambridge, England
[4] Univ Cambridge, Cambridge, England
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.1454
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY137
引用
收藏
页码：A599 / A599
页数：1
相关论文
共 28 条
  • [11] Methodological Quality Assessment of Budget Impact Analyses for Orphan Drugs: A Systematic Review
    Abdallah, Khadidja
    Huys, Isabelle
    Claes, Kathleen
    Simoens, Steven
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [12] The Budget Impact of Orphan Drugs in the US: A 20072013 MIDAS Sales Data Analysis
    Divino, Victoria
    Dekoven, Mitch
    Wang, Weiying
    Kleinrock, Michael
    Harvey, R. Donald
    Wade, Rolin L.
    Kaura, Satyin
    BLOOD, 2014, 124 (21)
  • [13] Estimating the budget impact of orphan drugs in Sweden and France 2013-2020
    Hutchings, Adam
    Schey, Carina
    Dutton, Richard
    Achana, Felix
    Antonov, Karolina
    ORPHANET JOURNAL OF RARE DISEASES, 2014, 9
  • [14] THE CURRENT AND FUTURE COSTS OF ORPHAN DRUGS IN CANADA - A PUBLIC PAYER BUDGET IMPACT ANALYSIS
    Forte, L.
    Malmberg, C.
    Mann, K.
    Jupe, K.
    Chow, G.
    Lech, R. A.
    Kulik, R.
    VALUE IN HEALTH, 2019, 22 : S855 - S855
  • [15] WHAT WAS THE ACTUAL BUDGET IMPACT OF ORPHAN MEDICINAL PRODUCTS BETWEEN 2000-2017 IN EUROPE?
    Mestre-Ferrandiz, J.
    Palaska, C.
    Kelly, T.
    Hutchings, A.
    Parnaby, A.
    VALUE IN HEALTH, 2019, 22 : S854 - S854
  • [16] Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US
    William V. Padula
    Sonal Parasrampuria
    Mariana P. Socal
    Rena M. Conti
    Gerard F. Anderson
    PharmacoEconomics, 2020, 38 : 1115 - 1121
  • [17] DRUG-RELATED PUBLIC EXPENDITURE IN EUROPE: THE BUDGET IMPACT OF ILLEGAL DRUGS
    Prieto, L.
    VALUE IN HEALTH, 2008, 11 (06) : A582 - A582
  • [18] THE BUDGET IMPACT OF ORPHAN DRUGS IN THE US AND CANADA: A 2007-2013 MIDAS SALES DATA ANALYSIS
    Divino, V
    DeKoven, M.
    Kim, T.
    Kleinrock, M.
    Wade, R. L.
    Kaura, S.
    VALUE IN HEALTH, 2015, 18 (07) : A666 - A666
  • [19] Comment on “Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US”
    Richard Manning
    PharmacoEconomics, 2020, 38 : 1373 - 1374
  • [20] Pricing and reimbursement policy for new orphan drugs in South Korea: focused on patient accessibility and budget impact
    Lee, Jong Hyuk
    Yoo, Seung-Lai
    EXPERT OPINION ON ORPHAN DRUGS, 2022, 10 (01): : 23 - 28
123